Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125190 · ClinicalTrials.gov registry record · Phase 2
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
A Phase 2 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00125190 is a Phase 2 study that has completed, run by Ipsen. The registered enrollment target is 45 participants.
The verdict
NCT00125190, a Phase 2 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.
Interventions
- DRUG rhIGF-1 (mecasermin) for a period of 86 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125190
The ClinicalTrials.gov registry entry for NCT00125190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhIGF-1 (mecasermin) for a period of 86 weeks is the first listed.
NCT00125190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125190 about?
NCT00125190 is a clinical study titled "Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency". This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.
What is the current status of trial NCT00125190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2005-07. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00125190?
The interventions under investigation include: rhIGF-1 (mecasermin) for a period of 86 weeks (DRUG).
Who is sponsoring clinical trial NCT00125190?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.